Alipotec Raiz de Tejocote dietary supplements, Net. Wt. 0.35oz, plastic bottle labeled with the "Alipotec King" sticker. Store at room te...
⚠ Critical Alert — Stop Using Immediately
This product has been flagged with severe risks (chemical exposure). Stop using it now and contact the brand or FDA for a refund, repair, or replacement.
FDA Recall Notice
Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1147-2024.
The "Alipotec King" Alipotec Raiz de Tejocote product was found to contain toxic yellow oleander instead of tejocote.
Corrective Action (per FDA)
Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1147-2024.
Recall terminated by FDA.
✅ What you should do
- Stop using the product if you own it.
- Check the model number, lot code, or sell-by date against the recall notice above.
- Contact Backstage Center Dba Ctc Seller or the retailer where you bought it for a refund, replacement, or repair.
- For the most current official instructions, visit the FDA recall page.
- If you've been hurt by this product, report the incident to FDA.
Consumer Contact (per FDA)
Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-1147-2024.
Backstage Center DBA CTC Seller
About the U.S. Food and Drug Administration
The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.
Visit FDA.gov →📣 Report a food, supplement, or cosmetic problem to the FDA
If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.
Backstage Center Dba Ctc Seller Recall FAQ
Backstage Center Dba Ctc Seller is the subject of a supplements safety report: Alipotec Raiz de Tejocote dietary supplements, Net. Wt. 0.35oz, plastic bottle labeled with the "Alipotec King" sticker. Store at room te.... The notice was published on February 23, 2024 by the U.S. Food and Drug Administration (FDA). Approximately 280 units are potentially affected.